Liver Function under Interferon/Ribavirin Therapy of Chronic Hepatitis C

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 462-465

  Stintzing, S ^a   Schmitt, C ^a   Ocker, M ^a,b   Ganslmayer, M ^a   Zopf, S ^a   Gahr, S ^a   Hahn, E G ^a   Herold, C ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Medicine 1 ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; FEMALE; GALACTOSE ELIMINATION CAPACITY; HEPATITIS C; HUMAN; INDOCYANINE GREEN CLEARANCE; LIVER FUNCTION TEST; LIVER PERFUSION; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SORBITOL CLEARANCE;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; MALE; RIBAVIRIN; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 67649223758     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Okuda K: Hepatocellular carcinoma. J Hepatol 2000;32:225-237.
2. Everson GT: Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004;4 Suppl l:S31-38.
3. McHutchison JG, Patel K: Future therapy of hepatitis C. Hepatology 2000;36:S245-225.
4. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Mar-cellin P, Sanchez-Tapias J, Sarrazin C, et al: Peginter-feron alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999.
5. Manns MP, Cornberg M, Wedemeyer H: Current and future treatment of hepatitis C. Indian J Gastroenterol 2001;20 Suppl 1:C47-51.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Mari-nos G, Goncales FL, Jr., Haussinger D, et al: Pegin-terferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
7. Shiffman ML: Management of patients with chronic hepatitis C virus infection and previous nonresponse. Rev Gastroenterol Disord 2004;4 Suppl l:S22-30.
8. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
9. Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C: Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007;188:758-764.
10. Herold C, Heinz R, Radespiel-Troger M, Schneider HT, Schuppan D, Hahn EG: Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver 2001;21:26-30.
11. Merkel C, Gatta A, Zoli M, Bolognesi M, Angeli P, Iervese T, Marchesini G, et al: Prognostic value of galac-tose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991;36:1197-1203.
12. Merkel C, Marchesini G, Fabbri A, Bianco S, Bianchi G, Enzo E, Sacerdoti D, et al: The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. Hepatology 1996; 24:820-823.
13. Reichen J, Widmer T, Cotting J: Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: a comparison with the Mayo model. Hepatology 1991;14:504-510.
14. Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D: Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001;21:260-265.
15. Herold C, Regn S, Ganslmayer M, Ocker M, Hahn EG, Schuppan D: Can quantitative tests of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci 2002;47:2669-2673.
16. Herold C, Ganslmayer M, Ocker M, Zopf S, Gailer B, Hahn EG, Schuppan D: Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained compared with severely compromised liver reserve. J Gastroenterol Hepatol 2003;18:445-449.
17. Hepner GW, Vesell ES: Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med 1975;83:632-638.
18. Tygstrup N, Ranek L: Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis 1986;6:129-137.
19. Zeeh J, Lange H, Bosch J, Pohl S, Loesgen H, Eggers R, Navasa M, et al: Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 1988;95:749-759.
20. Leevy CM, Mendenhall CL, Lesko W, Howard MM: Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962; 41:1169-1179.
21. Horsmans Y, Brenard R, Geubel AP: Short report: inter-feron-alpha decreases 14C-aminopyrine breath test values in patients with chronic hepatitis C. Aliment Pharmacol Ther 1994;8:353-355.
22. Reichen J, Bianchi L, Buhler H, Dolivo N, Gonvers JJ, Lavanchy D, Male PJ, et al: Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. J Hepatol 1996; 25:275-282.
23. Ocker M, Ganslmayer M, Zopf S, Gahr S, Janson C, Hahn EG, Herold C: Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. World J Gastroenterol 2005;ll:5521-5524.
24. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003;10 Suppl l:S59-67.
25. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739.
26. Zeuzem S: Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 2004;42:714-719.
27. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al: Peginterfer-on-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
28. Lisker-Melman M, Sayuk GS: Defining optimal therapeutic outcomes in chronic hepatitis. Arch Med Res 2007;38:652-660.
29. Nakamoto Y, Kaneko S: Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 2003;3:537-544.
30. Merkel C, Bolognesi M, Bellon S, Bianco S, Honisch B, Lampe H, Angeli P, et al: Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992;33:836-842.
31. Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, Serfaty L, et al: Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004;35:107-112.
32. Benyon RC, Iredale JP: Is liver fibrosis reversible? Gut 2000;46:443-446.
33. Dufour JF, DeLellis R, Kaplan MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-985.
34. Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, et al: Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006;44:472-477.
35. Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation. MedGenMed 2002;4:27.
36. Friedman SL, Bansal MB: Reversal of hepatic fibrosis -fact or fantasy? Hepatology 2006;43:S82-88.
37. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud JA: Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-1349.